Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
复制标题
DOI:
10.1038/nature14428
复制
发表时间:
2015-04-30
期刊:
影响因子:
64.8
通讯作者:
Geisbert TW
中科院分区:
文献类型:
--
作者:
Mire CE;Matassov D;Geisbert JB;Latham TE;Agans KN;Xu R;Ota-Setlik A;Egan MA;Fenton KA;Clarke DK;Eldridge JH;Geisbert TW
The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal hemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in nearly 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primate (NHPs) against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately ten-fold lower vaccine-associated viremia compared to the first generation vaccine and both provided complete, single dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.